New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 11, 2016, titled "New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions." Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 04, 2016 titled "Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA" Zydus Cadila gets final USFDA nod for Parkinson's treatment drug
Zydus Cadila has received final approval from the US health regulator to market Amantadine tablets, used for the treatment of Parkinson's disease and select viral infections, in the American market.T... Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 01, 2016 titled "Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules". Updates on Registrar & Share Transfer Agent
Cadila Healthcare Ltd has submitted to BSE a copy of Notice informing the shareholders regarding the appointment of M/s. Link Intime India Pvt Ltd as its Registrar & Share Transfer Agent with effective from June 01, 2016. Buy Cadila Healthcare with a target of Rs 346: Mitesh Thacker
Buy Cadila Healthcare with a target of Rs 346 and a stop loss of Rs 328 Investors' Presentation
Cadila Healthcare Ltd has submitted to BSE a copy of Investors' Presentation.
Zydus Cadila gets USFDA's final nod for fungal treatment drug
Shares of Cadila Healthcare, the group's listed entity, were trading 0.41 per cent up at Rs 319.45 on BSE in the afternoon session. Zydus receives final approval from the USFDA for Voriconazole Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated May 25, 2016 titled "Zydus receives final approval from the USFDA for Voriconazole Tablets". Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated May 24, 2016 titled 'Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting'